• CD36 Defines Primitive Chronic Myeloid Leukemia Cells Less Responsive To Imatinib But Vulnerable To Antibody-Based Therapeutic Targeting 

      Landberg, Niklas; von Palffy, Sophia; Askmyr, Maria K.; Lilljebjörn, Henrik; Sanden, Carl; Rissler, Marianne; Mustjoki, Satu; Hjorth-Hansen, Henrik; Richter, Johan; Ågerstam, Helena; Järås, Marcus; Fioretos, Thoas (Journal article; Peer reviewed, 2018)
      Tyrosine kinase inhibitors (TKIs) are highly effective for the treatment of chronic myeloid leukemia (CML), but very few patients are cured. The major drawbacks regarding TKIs are their low efficacy in eradicating the ...
    • The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants 

      Rio-Machin, Ana; Villiamy, Tom; Hug, Nele; Walne, Amanda; Tawana, Kiran; Cardoso, Shirleny; Ellison, Alicia; Pontikos, Nikolas; Wang, Jun; Tummala, Hemanth; Al Seraihi, Ahad Fahad H.; Alnajar, Jenna; Bewicke-Copley, Findlay; Barnett, Michael; Armes, Hannah; Bloor, Adrian; Bödör, Csabo; Bowen, David; Fenaux, Pierre; Green, Andrew; Hallahan, Andrew; Hjorth-Hansen, Henrik; Hossein, Upal; Killick, Sally; Lawson, Sarah; Layton, Mark; Male, Alison M.; Marsh, Judith; Mehta, Priyanka; Mous, Rogier; Nomdedéu, Josep F.; Owen, Carolyn; Pavlu, Jiri; Payne, Elspeth; Protheroe, Rachel E.; Preudhomme, Claude; Pujol-Moix, Nuria; Renneville, Aline; Russell, Nigel; Saggar, Anand; Sciuccati, Gabriela; Taussig, David; Toze, Cynthia; Uyttebroeck, Anne; Vandenberghe, Peter; Schlegelberger, Brigitte; Ripperger, Tim; Steinemann, Doris; Wu, John; Mason, Joanne; Page, Paula; Akiki, Susanna; Reay, Kim; Cavenagh, Jamie D.; Plagnol, Vincent; Caceres, Javier F.; Fitzgibbon, Jude; Dokal, Inderjeet (Peer reviewed; Journal article, 2020)
      The inclusion of familial myeloid malignancies as a separate disease entity in the revised WHO classification has renewed efforts to improve the recognition and management of this group of at risk individuals. Here we ...
    • Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006) 

      Hjorth-Hansen, Henrik; Stenke, Leif; Söderlund, Stina; Dreimane, Arta; Ehrencrona, Hans; Gedde-Dahl, Thobias; Gjertsen, Bjørn Tore; Höglund, Martin; Koskenvesa, Perttu; Lotfi, Kourosh; Majeed, Mohammed Waleed; Markevärn, Berit; Ohm, Lotta; Olsson-Strömberg, Ulla; Remes, Kari; Suominen, Merja; Simonsson, Bengt; Porkka, Kimmo; Mustjoki, Satu; Richter, Johan (Journal article, 2015)
      We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100 mg QD or imatinib 400 mg QD and report outcome as an intention-to-treat analysis with 36 months follow-up. ...
    • Early BCR-ABL1 transcript decline after 1 month of tyrosine kinase inhibitor therapy as an indicator for treatment response in chronic myeloid leukemia 

      El Missiry, Mohamed; Hjorth-Hansen, Henrik; Richter, Johan; Olson-Strömberg, Ulla; Stenke, Leif; Porkka, Kimmo; Kreutzman, Anna; Mustjoki, Satu (Journal article; Peer reviewed, 2017)
      n chronic myeloid leukemia (CML), early treatment prediction is important to identify patients with inferior overall outcomes. We examined the feasibility of using reductions in BCR-ABL1 transcript levels after 1 month of ...
    • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia 

      Hochhaus, Andreas; Baccarani, Michele; Silver, Richard T.; Schiffer, Charles A.; Apperley, Jane F.; Cervantes, Francisco; Clark, Richard E.; Cortes, Jorge Eduardo; Deininger, Michael Werner Nikolaus; Guilhot, François; Hjorth-Hansen, Henrik; Hughes, Timothy Peter; Janssen, Jeroen J.W.M.; Kantarjian, Hagop M.; Kim, Dong-Wook; Larson, Richard A.; Lipton, Jeffrey Howard; Mahon, François-Xavier; Mayer, Jiří; Nicolini, Franck Emmanuel; Niederwieser, Dietger Walter; Pane, Fabrizio; Radich, Jerald P.; Réa, Delphine; Richter, Johan; Rosti, Gianantonio; Rousselot, Philippe; Saglio, Giuseppe; Saußele, Susanne; Soverini, Simona; Steegmann, Juan Luis; Turkina, Anna; Zaritskey, Andrey Yu.; Hehlmann, Rüediger (Peer reviewed; Journal article, 2020)
      The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. Another goal is achieving a stable deep ...
    • Novel cytokines in growth control and bone disease of multiple myeloma 

      Hjorth-Hansen, Henrik (Dissertations at the Faculty of Medicine, 0805-7680; 182, Doctoral thesis, 2001)
      Myelomatose (benmargskreft) er en blodsyk dom som rammer ca 200 nordmenn årlig. Sykdommen kan ikke kureres og karakteriseres av symptomer som benmargssvikt og infeksjonstendenns, men kanskje først og fremst av sykelig ...
    • Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib 

      Gullaksen, Stein-Erik; Skavland, Jørn; Gavasso, Sonia; Tosevski, Vinko; Warzocha, Krzysztof; Dumrese, Claudia; Ferrant, Augustin; Gedde-Dahl, Thobias; Hellmann, Andrzej; Janssen, Jeroen; Labar, Boris; Lang, Alois; Majeed, Mohammed Waleed; Mihaylov, Georgi; Stentoft, Jesper; Stenke, Leif; Thaler, Josef; Thielen, Noortje; Verhoef, Gregor; Voglova, Jaroslava; Ossenkoppele, Gert; Hochhaus, Andreas; Hjorth-Hansen, Henrik; Mustjoki, Satu; Sopper, Sieghart; Giles, Francis; Porkka, Kimmo; Wolf, Dominik; Gjertsen, Bjørn Tore (Journal article; Peer reviewed, 2017)
      Monitoring of single cell signal transduction in leukemic cellular subsets has been proposed to provide deeper understanding of disease biology and prognosis, but has so far not been tested in a clinical trial of targeted ...